Abstract
Background
In patients with pulmonary arterial hypertension (PAH), it remains unknown if the response to the acute pulmonary vasoreactivity test changes over time and determines prognosis.
Methods
We included PAH patients who underwent two right heart catheterizations (RHC) with acute vasoreactivity challenge using inhaled nitric oxide (NO). The hemodynamic response was assessed by absolute or percentage change in mean pulmonary artery pressure (mPAP) or pulmonary vascular resistance (PVR).
Results
We included 54 patients, age 51 ± 17 years, and 44 (82%) female. The median (IQR) time between the two RHC was 24.5 months (14.8–42 months). The percentage drop in mPAP was less pronounced in the second RHC (− 8.6 ± 8.1 versus − 12.3 ± 13.8 mmHg, p = 0.02). A total of 8 (14%) patients met criteria for a positive vasodilatory test during the first RHC but only 1 during the second. Patients with increased vasoreactivity at second RHC were more likely to receive (a) treatment with phosphodiesterase-5 inhibitors (PDE5-inh) at first RHC (56% versus 27%, p = 0.04) and (b) more PAH-specific medications by second RHC (2.3 ± 0.8 versus 1.8 ± 0.9, p = 0.03). Cox survival analysis showed that change in mPAP or PVR during vasodilatory challenge at or between the first and second RHC had no impact on survival.
Conclusions
Pulmonary vascular reactivity to inhaled NO might decrease over time; however, there is great variability among patients. The use of PDE5-inh at first RHC and number of PAH-specific treatments by the second RHC were associated with an improvement in pulmonary vasoreactivity over time.
Similar content being viewed by others
Abbreviations
- NO:
-
Nitric oxide
- NYHA:
-
New York Heart Association
- PH:
-
Pulmonary hypertension
- PAH:
-
Pulmonary arterial hypertension
- RHC:
-
Right heart catheterization
- CCB:
-
Calcium Channel blocker
References
Tonelli AR, Arelli V, Minai OA, Newman J, Bair N, Heresi GA et al (2013) Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med 188(3):365–369
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M et al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53(1):1801913
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903–975
Tonelli AR, Alnuaimat H, Mubarak K (2010) Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 104(4):481–496
Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F et al (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12(2):265–270
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67–119
Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S et al (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23):3105–3111
Krasuski RA, Devendra GP, Hart SA, Wang A, Harrison JK, Bashore TM (2011) Response to inhaled nitric oxide predicts survival in patients with pulmonary hypertension. J Card Fail 17(4):265–271
Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J et al (2004) Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98(3):225–234
Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G et al (2004) Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):35S–62S
Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131(6):1917–1928
Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G et al (2010) Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 31(15):1898–1907
Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327(2):76–81
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42–50
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34–41
Ahmed M, Dweik RA, Tonelli AR (2016) What is the best approach to a high systolic pulmonary artery pressure on echocardiography? Cleve Clin J Med. 83(4):256–260
Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5(5):303–311; discussion 312–313
Akagi S, Nakamura K, Matsubara H, Ohta-Ogo K, Yutani C, Miyaji K et al (2014) Reverse remodeling of pulmonary arteries by high-dose prostaglandin I2 therapy: a case report. J Cardiol Cases 9(5):173–176
van der Feen DE, Bartelds B, de Boer RA, Berger RMF (2017) Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. Eur Heart J 38(26):2034–2041
Hemnes AR, Trammell AW, Archer SL, Rich S, Yu C, Nian H et al (2015) Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation 131(4):401–409; discussion 409
Hemnes AR, Zhao M, West J, Newman JH, Rich S, Archer SL et al (2016) Critical genomic networks and vasoreactive variants in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 194(4):464–475
McMahon TJ, Bryan NS (2017) Biomarkers in pulmonary vascular disease: gauging response to therapy. Am J Cardiol 120(8S):S89–S95
Elliott CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, Rich S et al (2006) Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 113(21):2509–2515
Jones DA, Benjamin CW, Linseman DA (1995) Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 48(5):890–896
Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S et al (2004) Genetic basis of pulmonary arterial hypertension: current understanding and future*** directions. J Am Coll Cardiol 43(12 Suppl S):33S–39S
Robbins IM, Hemnes AR, Pugh ME, Brittain EL, Zhao DX, Piana RN et al (2014) High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 7(1):116–122
Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 68(4):368–378
Funding
A.R.T is supported by NIH grant # R01HL130307.
Author information
Authors and Affiliations
Contributions
RT: Participated in the statistical analysis and interpretation of the results, writing the manuscript and participating in the subsequent revisions. Dr. Tooba coordinated the efforts of all authors for this study. AA: Participated in the data collection, interpretation of the results, and critical revision of the manuscript for important intellectual content and final approval of the manuscript submitted. ART: Participated in the design of the study, statistical analysis and interpretation of the results, writing and critical revision of the manuscript for important intellectual content and final approval of the manuscript submitted. Dr. Tonelli is the guarantor of the paper, taking responsibility for the integrity of the work, from inception to published article.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no significant conflicts of interest with any companies or organizations whose products or services may be discussed in this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tooba, R., Almoushref, A. & Tonelli, A.R. Is There Value in Repeating Inhaled Nitric Oxide Vasoreactivity Tests in Patients with Pulmonary Arterial Hypertension?. Lung 198, 87–94 (2020). https://doi.org/10.1007/s00408-019-00318-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-019-00318-0